Noncoding mutations as biomarkers of sensitivity and response to treatment in breast cancer

emavusertib (CA-4948) - Curis, Dr. Reddy’s

Vumon (teniposide) - BMS

Piqray (alpelisib) - Novartis

Talzenna (talazoparib) - Pfizer

A. Cuy Saqués1; C. Monger2; F. Matra2; A. Armesto2; A. Bracken2; S. Madden3; J. Crown4; A. Eustace5.

Feb 29, 2024